Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Phillip Tran has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Wellens Syndrome in the Modern Era: A Contemporary Review

    by Ai Cao My Bui, Nghia Phu Nguyen, Van-Phu Tran, Quy Tran, Minh Vu Phuc Ha, Nhu Hoang, Hung Minh Ngo, Phillip Tran


  • Open Access

    Bridging the mentorship divide: how large language models could reshape medical workforce equity

    by Nghia Phu Nguyen, Phillip Tran

    Mentorship in predictive large language models (LLMs) presents both opportunities and risks of inequity if these systems are not designed with care. Mentorship quietly shapes medical careers, yet opportunities for it remain unequal. LLMs can analyze student writing and may reveal potential that exams overlook. This predictive capacity could inform fairer mentorship and direct support to students who need it most, helping build a more equitable medical workforce.


  • Open Access

    Teaching the machine to heal in Vietnam

    by Nghia Phu Nguyen, Phillip Tran

  • Open Access

    Regulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights

    by Nguyen Thanh Tam, Ahmed M. Sayed, Mohammad Najm Dadam, Randa Elsheikh, Jeza Muhammad Abdul Aziz, Abdelrahman Gamil Gad, Thi Thu Hoai Nguyen, Phillip Tran, Zhilin Zhang, Norio Ohmagari, et al.

    Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.


  • Open Access

    A step-by-step guide for conducting an umbrella review

    by Mohammed Abdellatif, Mohammad Najm Dadam, Nguyen Tuan Vu, Nguyen Hai Nam, Nguyen Quoc Hoan, Zahraa Taoube, Phillip Tran, Nguyen Tien Huy

    Background: The rapid increase in published research poses challenges for healthcare professionals aiming to stay updated. While systematic reviews help synthesize findings, their abundance can overwhelm readers. Umbrella reviews address this by summarizing multiple systematic reviews, offering a comprehensive perspective on specific topics. Methods: This article offers a practical, step-by-step guide for conducting an umbrella review, aimed at researchers and clinicians alike. Results: Umbrella reviews effectively integrate data from systematic reviews, ensuring clearer evidence synthesis. Tools like Rayyan and Covidence streamline processes such as screening and data extraction. Strategies for managing overlapping studies and assessing methodological quality enhance the validity of findings. Conclusion: Umbrella reviews are invaluable for evidence-based decision-making, especially in healthcare. This guide equips researchers and clinicians with a structured approach to navigate and synthesize the growing body of systematic reviews, fostering reliable and actionable insights.


  • Open Access

    Quantitative Flow Ratio-Guided vs. Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of One-Year Clinical Outcomes

    by Viet Nghi Tran, Amreen Dhindsa, Kuchalambal Agadi, Hoang Nhat Pham, Hong Hieu Truong, Chau Doan Nguyen, Hanad Bashir, Huan Dat Pham, Thanh Vien Truong, Phillip Tran, et al.

    Background: Quantitative Flow Ratio (QFR) is a novel, wire-free, and hyperemia-free physiological assessment for guiding Percutaneous Coronary Intervention (PCI), which may offer advantages over traditional angiography-guided PCI. This systematic review with meta-analysis compares clinical outcomes after one year in patients who underwent QFR-guided versus angiography-guided PCI. Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered on 4 November 2024 in PROSPERO (ID: CRD42024609799). A systematic search was performed across multiple databases to identify clinical trials comparing QFR-guided and angiography-guided PCI. Random-effects models were used to assess one-year outcomes of major adverse cardiovascular events (MACEs), revascularization, and rehospitalization, with heterogeneity measured using I2, H2, and Cochran’s Q statistics. Study quality was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool. Results: Compared to traditional angiography-guided PCI, QFR-guided PCI was associated with numerically lower but statistically non-significant risks of MACEs (risk difference: −0.08, 95% CI: −0.20 to 0.04), revascularization (risk difference: −0.02, 95% CI: −0.08 to 0.03), and rehospitalization (risk difference: −0.02, 95% CI: −0.08 to 0.04) over one year. Substantial heterogeneity was observed for MACEs (I2 = 84.95%, H2 = 6.64) and revascularization (I2 = 94.18%, H2 = 17.18), whereas rehospitalization exhibited low heterogeneity (I2 = 17.17%, H2 = 1.21). The risk of bias was assessed by the RoB 2 tool, which revealed low to some concern risk of bias across key domains. Conclusions: Quantitative Flow Ratio (QFR) has demonstrated comparable one-year clinical outcomes to traditional angiography for PCI guidance, with a trend toward improved results. However, the high heterogeneity among studies and the risk of bias necessitate the need for larger, high-quality trials to validate these findings.

  • MORTALITY TRENDS IN HEART FAILURE AND DIFFERENCES BY RACE AND SEX IN THE UNITED STATES: 1999 - 2019

    by Amandeep Goyal, Shubham Lahan, Poonam Bhyan, Sagar Ranka, Suveenkrishna Pothuru, Harsh Mehta, Tarun Dalia, Neelkumar Patel, Prakash Acharya, Tai Thien Tan Tri Truyen, et al.